摘要
胰腺癌的多学科综合治疗策略已成共识。如何对抗抑制性肿瘤微环境成为关键。免疫检查点抑制剂已在多种实体瘤的治疗中取得突破,而在胰腺癌的临床实践中效果欠佳。免疫检查点抑制剂与化疗、放疗、靶向治疗等的联合治疗研究已开展,但目前仍处在小样本临床研究阶段。现结合胰腺癌中的研究现状与进展,进一步探讨免疫检査点抑制剂在实践中存在的问题,客观评价其价值。
The comprehensive and multiple disciplinary team therapeutic strategies of pancreatic cancer have been accepted as a consensus.Immune checkpoint inhibitors have made great breakthroughs in the treatment of various solid tumors.However,immune checkpoint inhibitors failed to elicit efficacy in patients with pancreatic cancer and how to overcome the immunosuppressive tumor microenvironment may be the crucial event.Combination regimens of immune checkpoint inhibitors with chemotherapy,radiotherapy,and molecular targeted therapy have been underway,but the sample size of the clinical trial was still limited.Considering the current research status and progress of pancreatic cancer,this article further discusses the practical problems of immune checkpoint inhibitors and makes objective evaluation of its value.
作者
张翔
刘乔飞
廖泉
Zhang Xiang;Liu Qiaofei;Liao Quan(Department of General Surgery,Peking Union Medical College Hospital,Chinese A cademy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)
出处
《中华内分泌外科杂志》
CAS
2019年第6期441-444,共4页
Chinese Journal of Endocrine Surgery
基金
国家自然科学基金(81673023
81502068
81872501)
北京市自然科学基金(7172177)。
关键词
胰腺癌
免疫检查点抑制剂
治疗
Pancreatic cancer
Immune checkpoint inhibitors
Treatment
